Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 4/20 | 0.42 |
| ▸ | DRD2 | P14416 | 6/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 3/20 | 0.41 |
| ▸ | DRD3 | P35462 | 3/20 | 0.41 |
| ▸ | NCF1 | P14598 | 9/20 | 0.40 |
| ▸ | CYBB | P04839 | 1/20 | 0.39 |
| ▸ | NOX5 | Q96PH1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23267819 | 1.00 | DGAT1 (0.42) | DGAT1DRD2GBA1DRD4DRD3 | |
| SCHEMBL23268012 | 1.00 | DGAT1 (0.42) | DGAT1DRD2GBA1DRD4DRD3 | |
| SCHEMBL19589313 | 1.00 | DGAT1 (0.42) | DGAT1DRD2GBA1DRD4DRD3 | |
| SCHEMBL18390049 | 0.90 | GBA1 (0.36) | DGAT1DRD2GBA1DRD4DRD3 | |
| SCHEMBL23267576 | 0.89 | GBA1 (0.48) | DRD2GBA1DRD4DRD3NCF1 | |
| SCHEMBL25920828 | 0.89 | GBA1 (0.48) | DRD2GBA1DRD4DRD3NCF1 | |
| SCHEMBL23267580 | 0.89 | GBA1 (0.48) | DRD2GBA1DRD4DRD3NCF1 | |
| SCHEMBL12033268 | 0.87 | DGAT1 (0.53) | DGAT1DRD2DRD4DRD3NCF1 | |
| SCHEMBL18850695 | 0.87 | DGAT1 (0.47) | DGAT1DRD2DRD4DRD3NCF1 | |
| SCHEMBL25138066 | 0.87 | DGAT1 (0.47) | DGAT1DRD2DRD4DRD3NCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021077010-A1 | BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY | ARVINAS OPERATIONS, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
| US-20170333567-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2017-11-23 | — | — | US | disclosed |
| US-9132188-B2 | Chemically Programmed Vaccination | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-09-15 | — | — | US | disclosed |
| US-8518927-B2 | Chemically programmed vaccination | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-08-27 | — | — | US | disclosed |
| US-20110311516-A1 | Chemically Programmed Vaccination | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333567-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | DGAT1 3441/4885DRD2 2512/4885GBA1 417/4885 |
| US-20110311516-A1 | Chemically Programmed Vaccination | CD69, CD4, ICOS | DGAT1 3652/4885DRD2 2747/4885GBA1 3962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.